DGAP-News: BioCrea GmbH: BioCrea Announces Upcoming Presentations at Leading International Conferences

DGAP-News: BioCrea GmbH / Key word(s): Conference
BioCrea GmbH: BioCrea Announces Upcoming Presentations at Leading
International Conferences

24.09.2014 / 09:00

---------------------------------------------------------------------

BioCrea Announces Upcoming Presentations at Leading International
Conferences

"On target with rapid acting antidepressants"

Radebeul, Germany, September 24, 2014 - BioCrea GmbH (BioCrea), the
first-in-class CNS drug discovery specialist, today announced that Chief
Executive Officer, Dr. Tom Kronbach, will present at the following three
international life sciences conferences over the coming months.

Dr. Tom Kronbach will be presenting: "On target with rapid acting
antidepressants (RAAD)" at:

The 14th Annual Biotech in Europe Forum, September 30 - October 1, 2014:
Basel, Switzerland
www.sachsforum.com  
Corporate presentation on September 30, 2014 at 11:00-11:15 CET in the Lima
room
and
The Neuroscience Panel
September 30, 2014 at 15:30-16:30 CET 

European Partnering and Investment Conference (EPIC), October 2, 2014:
London, UK
www.epicbiotech.com
Corporate presentation on October 2, 2014 at 11:30 BST in the Maynard 1
room

Therapeutic Area Partnerships (TAP), November 19 - 21, 2014: Boston, USA
www.iirusa.com/therapeuticareapartnership
Date and time of presentation to be confirmed 

"It is an exciting time to be presenting the BioCrea story and our lead
program to three eminent international specialist audiences. In particular,
we will focus on our advanced NMDA receptor 2B drug candidates for
treatment-resistant depression," said Dr. Tom Kronbach, CEO of BioCrea, in
the run-up to the events.

For updates on these conferences please also visit our website:
http://www.biocrea.com/news/events/ 

About the 14th Annual Biotech in Europe Forum
The forum is recognised as the leading international stage for those
interested in investing and partnering in the biotech and life science
industry and is highly transactional. The Forum draws together an exciting
cross-section of early-stage/pre-IPO, late-stage and public companies with
leading investors, analysts, money managers and pharma licensing
executives. Supported and designed by leading figures within Europe's
pharmaceutical and biotech industry, this event will once again be covered
by our regular media partners. We expect over 600 delegates and 100
presenting companies.

About the EPIC Biotech Conference
An autumnal event for 2014 when we will once again be showcasing the best
of UK and European biotechs in a one day format. Some 50-60 European and UK
biotech companies will be presenting and are looking for partners,
investment or services. Our audience will comprise 250 - 300 delegates from
the pharma, biotech, investor, CRO and service sectors. Industry keynotes
will set the tone for the day and partnering will take place all day as
well as informal networking.

About the Therapeutic Area Partnerships (TAP)
A meeting for the sharpest minds in biopharma. Since its launch eight years
ago, TAP has come to be regarded as the industry's premier
biopharmaceutical partnering event. A uniquely efficient gathering, TAP
brings together decision-makers to assess the most promising drug programs
available for partnering in: Oncology, Cardiovascular, Neuroscience,
Infectious Diseases, Anti-Inflammatory/Autoimmune Diseases, Advanced
Therapies (Cellular and Gene Therapies, Rare Diseases and other high value
and niche areas).
Attendees have the opportunity to hear from and meet some of the industry's
most talented biotechnology entrepreneurs and pharmaceutical leaders.
Casual gatherings and one-on-one partnering meetings bring together
business development decision makers from large pharmaceutical firms and
executive leadership from innovative biotechnology firms to make this one
of the industry's most productive events.

About BioCrea
BioCrea, the Radebeul-based first-in-class drug discovery specialist
validated through pharma partnerships, has established a number of programs
in neurological and psychiatric disorders. Its proven expertise is based on
proprietary compound libraries, medicinal chemistry, molecular modeling and
advanced screening technologies. BioCrea uses this expertise in an
innovative multi-parameter optimization approach to generate and deliver
CNS drug candidates that offer significant potential for greater efficacy
and tolerability. Moreover, the patient-derived stem cell (iPSC) platform
has been successfully developed to discover high value preclinical drug
candidates for neurodegenerative diseases such as amyotrophic lateral
sclerosis (ALS, Lou Gehrig's disease). For more information, please visit
www.biocrea.com.

Contact

Dr. Tom Kronbach
CEO, BioCrea GmbH
Tel.: +49 351 / 4043 3332
Fax: +49 351 / 4043 3216
tom.kronbach@biocrea.com



---------------------------------------------------------------------

24.09.2014 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------


288237 24.09.2014